Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
|
- Darrell Carroll
- 5 years ago
- Views:
Transcription
1 The new england journal of medicine original article Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Meletios Dimopoulos, M.D., Andrew Spencer, M.D., Michael Attal, M.D., H. Miles Prince, M.D., Jean-Luc Harousseau, M.D., Anna Dmoszynska, M.D., Jesus San Miguel, M.D., Andrzej Hellmann, M.D., Thierry Facon, M.D., Robin Foà, M.D., Alessandro Corso, M.D., Zvenyslava Masliak, M.D., Marta Olesnyckyj, R.N., Zhinuan Yu, Ph.D., John Patin, M.S., Jerome B. Zeldis, M.D., Ph.D., and Robert D. Knight, M.D., for the Multiple Myeloma (00) Study Investigators* ABSTRACT Background Lenalidomide is a structural analogue of with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. Methods Of 35 patients who had received at least one previous antimyeloma therapy, 76 were randomly assigned to receive 25 mg of oral lenalidomide and 75 to receive placebo on days to 2 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days to 4, 9 to 2, and 7 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. Results The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median,.3 months vs. 4.7 months; P<0.00). A complete or partial response occurred in 06 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.00), with a complete response in 5.9% and 3.4% of patients, respectively (P<0.00). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P = 0.03). Grade 3 or 4 adverse events that occurred in more than 0% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (.4% vs. 5.7%), and venous thromboembolism (.4% vs. 4.6%). From the University of Athens School of Medicine, Athens (M.D.); Alfred Hospital (A.S.) and Peter MacCallum Cancer Institute (H.M.P.) both in Melbourne, Australia; Centre Hospitalier Universitaire Purpan, Toulouse, France (M.A.); Centre Hospitalier Hôtel-Dieu, Nantes, France (J.-L.H.); University School of Medicine, Lublin, Poland (A.D.); Hospital Universitario de Salamanca, Salamanca, Spain (J.S.M.); Medical University of Gdansk, Gdansk, Poland (A.H.); Hôpital Claude Huriez, Lille, France (T.F.); University La Sapienza, Rome (R.F.); Fondazione Istituto Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy (A.C.); Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine (Z.M.); and Celgene, Summit, NJ (M.O., Z.Y., J.P., J.B.Z., R.D.K.). Address reprint requests to Dr. Dimopoulos at the University of Athens School of Medicine, Alexandra Hospital, Vas. Sophias 80, Athens 528, Greece, or at mdimop@med.uoa.gr. *Other investigators who participated in the Multiple Myeloma (00) Study are listed in the Appendix. This article (0.056/NEJMoa070594) was updated on July 29, 2009, at NEJM.org. N Engl J Med 2007;357: Copyright 2007 Massachusetts Medical Society. Conclusions Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT ) n engl j med 357;2 november 22,
2 The new england journal of medicine Multiple myeloma, the second most common hematologic cancer, caused more than 9,000 deaths in Europe in To improve the outcome of treatment, new agents are needed. 2 The immunomodulatory drug has activity in about one third of patients with relapsed or refractory multiple myeloma; response rates are increased when is combined with dexamethasone or chemotherapy. 3-7 Treatment with is associated with sedation, fatigue, constipation, rash, deep-vein thrombosis, and peripheral neuropathy. These toxic effects often require dose reduction and, in some instances, discontinuation of the drug. 8 Lenalidomide, a derivative of, is less toxic and more potent than the parent drug. 9 In patients with relapsed or refractory multiple myeloma, lenalidomide can overcome resistance not only to conventional chemotherapy but also to, 0, and dexamethasone plus lenalidomide is more effective than either agent alone in refractory multiple myeloma. We report on a randomized, phase 3 trial in which lenalidomide plus dexamethasone was compared with placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. Methods Patients Patients with multiple myeloma in Europe, Israel, and Australia were eligible to participate in the study if they were at least 8 years of age and had been treated with at least one previous antimye loma regimen. Patients were excluded if they had had disease progression during previous therapy containing high-dose dexamethasone (total month ly dose, >200 mg). Measurable disease was defined as a level of serum monoclonal protein (M protein) of at least 0.5 g per deciliter or a level of urinary Bence Jones protein of at least 0.2 g per day. Additional eligibility criteria included an Eastern Cooperative Oncology Group performance status of 2 or less, a serum aspartate aminotransferase or alanine aminotransferase level that was no more than three times the upper limit of the normal range, a serum bilirubin level that was no more than two times the upper limit of the normal range, a serum creatinine level of less than 2.5 mg per deciliter (22 μmol per liter), and an absolute neutrophil count of at least 000 per cubic millimeter. The platelet count needed to be more than 75,000 per cubic millimeter for patients with less than 50% bone marrow plasma cells and more than 30,000 per cubic millimeter for patients with 50% or more bone marrow plasma cells. Women of childbearing potential were eligible if they agreed to use contraception during the study, had a negative pregnancy test before enrollment, and agreed to undergo pregnancy testing every 4 weeks from enrollment until 4 weeks after discontinuation of the assigned study drug. Patients were excluded if they had previously had hypersensitivity to or uncontrollable side effects associated with previous use of or dexamethasone. All patients gave written informed consent, and an ethics committee at each study site approved the protocol. Study Design The primary end point of this multicenter, randomized, placebo-controlled, phase 3 trial was the time to disease progression. Secondary end points included overall survival, the rate of response, and safety. Patients received either 25 mg of oral lenalidomide or placebo on days to 2 of a 28-day cycle; all patients received 40 mg of oral dexamethasone on days to 4, 9 to 2, and 7 to 20 for the first four cycles. After the fourth cycle, 40 mg of dexamethasone was administered only on days to 4. Patients continued to receive the assigned drug regimen until the occurrence of disease progression or unacceptable toxic effects. Patients were stratified according to the baseline serum β 2 - microglobulin level (<2.5 mg per liter or 2.5 mg per liter), previous stem-cell transplantation (none or ), and the number of previous antimyeloma regimens ( or 2). Toxic effects were graded according to the National Cancer Institute s Common Toxicity Criteria, version 2. For grade 4 adverse events, treatment was withheld and restarted at the next lower dose after resolution of the toxic effects. The dexamethasone dose was modified because of toxic effects at the investigator s discretion as follows: 40 mg daily for 4 days every 2 weeks (dose level, ) or every 4 weeks (dose level, 2) or 20 mg daily for 4 days every 4 weeks (dose level, 3). For grade 3 or 4 neutropenia without other toxic effects, the first dose-modification step was dose level (daily subcutaneous injection of 5 μg of 224 n engl j med 357;2 november 22, 2007
3 Lenalidomide for Relapsed or Refractory Myeloma granulocyte colony-stimulating factor per kilogram of body weight and 25 mg of lenalidomide); sequential reductions of the lenalidomide dose were 5 mg (dose level, 2), 0 mg (dose level, 3), and 5 mg (dose level, 4), with 5 μg of granulocyte colony-stimulating factor per kilogram daily at the investigator s discretion. Patients underwent a blood count and physical examination on days and 5 (and day 8 of cycle ) during cycles to 3 and on day of each cycle thereafter. Serum and urinary levels of M protein were assessed on day of each cycle and at the end of treatment. Transfusion of platelets and red cells and the administration of neutrophil growth factors and epoetin alfa were allowed as needed. All patients were allowed to receive bisphosphonates. Prophylactic anticoagulation was not recommended. The study was designed as a collaborative effort by Dr. Dimopoulos, the coinvestigators, and the sponsor, Celgene. The sponsor collected the data and performed the final analysis, in collaboration with an independent data monitoring committee and Dr. Dimopoulos. All authors had full access to the primary data and the final analysis. Dr. Dimopoulos vouches for the accuracy and completeness of the published results. The first draft was written by Dr. Dimopoulos; subsequent drafts were written by Dr. Dimopoulos with editorial assistance from an employee of the sponsor. All authors had input before submission of both the original and revised manuscripts. An independent data monitoring committee reviewed safety and efficacy data throughout the study. Assessments The response of patients to treatment was assessed according to the criteria of the European Group for Blood and Marrow Transplantation. 2 The time to progression was measured from randomization to the date of the first assessment showing progression. Progressive disease was defined as any of the following: an absolute increase of more than 500 mg of serum M protein per deciliter, as compared with the nadir value, or an absolute increase of more than 200 mg of urinary M protein in 24 hours; a new bone lesion or plasmacytoma or an increase in the size of such lesions; or the development of hypercalcemia (serum calcium level, >.5 mg per deciliter [2.9 mmol per liter]). Responses were designated as complete (defined as the absence of M protein in serum and urine, as confirmed by immunofixation in two samples, and <5% marrow plasma cells) or partial (defined as a reduction in the level of M protein in serum of at least 50% and a reduction in urine of at least 90%). Complete and partial responses were confirmed by repeated measurements of M protein in serum and urine after 6 weeks, and progressive disease was confirmed by repeated measurements of M protein in serum and urine after to 3 weeks. Near-complete response, a subcategory of partial response, was defined as a complete response without confirmation of a decrease in marrow plasma cells to less than 5% by bone marrow biopsy, confirmation of the disappearance of M protein in serum or urine by repeat immunofixation, or both. Statistical Analysis The accrual goal was the enrollment of 302 patients (5 in each group), which would provide a statistical power of 85% to detect a hazard ratio of.5 for the time to progression with the use of a two-sided log-rank test with an overall significance level of 0.05, adjusted for one interim analysis. Full information that was necessary for a logrank test to have a power of 85% would be achieved when approximately 222 patients had disease progression in the two study groups. For overall survival, the trial had a power of approximately 80% to detect a difference of 50% in median overall survival for an analysis performed when at least 94 patients had died. An interim analysis of safety and efficacy was planned when disease had progressed in patients. If the predetermined O Brien Fleming boundary for the superiority of lenalidomide over placebo was crossed, the study would be unblinded, and patients would be allowed to receive lenalidomide at the time of disease progression or at the investigator s discretion. All primary analyses were based on the intention-to-treat population, and subgroup analyses were planned on the basis of stratification variables. An unstratified log-rank test was used to compare time-to-event variables between groups. Both the time to progression and overall survival were estimated with the use of Kaplan Meier methods. Continuity-corrected Pearson chi-square tests were used to compare the proportions of patients in the two groups who had a response to treatment. n engl j med 357;2 november 22,
4 The new england journal of medicine Table. Demographic and Clinical Characteristics of the Patients.* Characteristic Age yr Lenalidomide (N = 76) Results Placebo (N = 75) Median Range Male sex % Lytic bone lesions no. (%) 36 (77.3) 40 (80.0) Time since first diagnosis yr Median Range Durie Salmon stage no. (%) I (6.2) 8 (4.6) II 50 (28.4) 57 (32.6) III 5 (65.3) 0 (62.9) Eastern Cooperative Oncology Group performance status no. (%) 0 78 (44.3) 65 (37.) 72 (40.9) 79 (45.) 2 23 (3.) 27 (5.4) 3 0 (0.6) Missing data 3 (.7) 3 (.7) Previous therapy no. (%) No. of therapies 56 (3.8) 57 (32.6) 2 20 (68.2) 8 (67.4) Type of therapy Thalidomide 53 (30.) 67 (38.3) Bortezomib 8 (4.5) 7 (4.0) Stem-cell transplantation 97 (55.) 95 (54.3) β 2 -microglobulin level no. (%) <2.5 mg per liter 5 (29.0) 48 (27.4) 2.5 mg per liter 25 (7.0) 27 (72.6) * There were no significant differences between the two groups according to a pooled t-test for continuous variables (age, time from first pathological diagnosis, percent plasma cells) and Fisher s exact test for categorical variables (all other variables in the table) (P>0.05). Percentages may not total 00 because of rounding. Lower numbers indicate better performance. Patients and Treatments Between September 22, 2003, and September 5, 2004, a total of 35 patients (intention-to-treat population) were enrolled at 4 centers in Europe, 6 centers in Australia, and 3 centers in Israel. Of these patients, 76 were randomly assigned to receive lenalidomide plus dexamethasone (the lenalidomide group) and 75 to receive placebo plus dexamethasone (the placebo group). Baseline characteristics were well balanced between the two groups (Table ). Previous therapies included stem-cell transplantation,, dexamethasone, melphalan, doxorubicin, and bortezomib. Patients in the two groups had received a median of two previous therapies. The average time from initial diagnosis to study entry was more than 4 years. At the time of the analysis, which included all data obtained before unblinding in August 2005, the median follow-up was 6.4 months. Median daily doses of study drugs in the two groups were 25 mg of lenalidomide and 40 mg of dexamethasone. The O Brien Fleming boundary for the superiority of lenalidomide had been passed at the time of the interim analysis in September Efficacy The median time to progression was.3 months in the lenalidomide group and 4.7 months in the placebo group (P<0.00) (Fig. A). The hazard ratio for time to progression was 2.85 (95% confidence interval [CI], 2.6 to 3.76; P<0.00) in favor of the lenalidomide group. Patients in the lenalidomide group had a significantly longer time to progression than patients in the placebo group in all stratified subgroups. The median time to progression for patients who had undergone one previous therapy was not reached in the lenalidomide group and was 4.7 months in the placebo group. Among patients who had undergone at least two previous therapies, the median time to progression was. months in the lenalidomide group and 4.7 months in the placebo group (P<0.00). The median time to progression for patients who had previously undergone treatment with (30.% of the patients in the lenalidomide group and 38.3% of those in the placebo group) was 8.4 months in the lenalidomide group and 4.6 months in the placebo group (P<0.00). Among patients with no previous exposure to, the median time to progression was 3.5 months in the lenalidomide group and 4.7 months in the placebo group (P<0.00) (Fig. B). In the lenalidomide group, the median time to progression was not significantly related to previous exposure to (hazard ratio, 0.65; 95% CI, 0.42 to.02; P = 0.06). Among patients in whom the disease had progressed during previous treatment, the median time to 226 n engl j med 357;2 november 22, 2007
5 Lenalidomide for Relapsed or Refractory Myeloma A Lenalidomide Placebo Patients (%) Months to Progression B Lenalidomide without previous Patients (%) Lenalidomide with previous Placebo without previous Placebo with previous Months to Progression Figure. Kaplan Meier Curves for the Time to Disease Progression among All Patients and in Subgroups with and without Previous Exposure to Thalidomide. Panel A shows estimates of the median time to disease progression for the intention-to-treat population (.3 months in the lenalidomide group and 4.7 months in the placebo group) (P<0.00 by the log-rank test). Panel B shows the median time to disease progression among patients in the two study groups who received before study entry and those who did not receive (in the lenalidomide group, 3.5 months among patients who did not receive and 8.4 months among those who did receive ; in the placebo group, 4.7 months and 4.6 months, respectively; P<0.00 by the log-rank test for both between-group comparisons of patients who did and those who did not receive ). progression was 9.5 months in the lenalidomide group and 3.7 months in the placebo group (P<0.00). The median time to progression was.3 months among patients who had undergone stem-cell transplantation and.4 months among patients who had not undergone stem-cell transplantation. A total of 06 patients (60.2%) in the lenalidomide group and 42 patients (24.0%) in the placebo group had at least a partial response (P<0.00); 28 patients (5.9%) in the lenalidomide group and 6 patients (3.4%) in the placebo group had a complete response (P<0.00) (Table 2). The median time to the first response was 2. months in the lenalidomide group and.6 months in the placebo group. The median time to a complete or near-complete response was 5. months in the lenalidomide group and 6.9 months in the placebo group. The median duration of the response was longer in the lenalidomide group (6.5 months) than in the placebo group (7.9 months, P = 0.02). The analysis of overall response rates (complete, near-complete, and partial responses) for each stratification group and for patients with and those without previous treatment showed a higher response rate among patients receiving lenalidomide in all the subgroups (Table 2). In the lenalidomide group, the overall response rate was higher in patients who had not received than in those who had received (65.0% vs. 49.%, P = 0.07). Survival As of May 2006, 47 patients (26.7%) in the lenalidomide group had died (30 from progressive disease), as had 60 patients (34.3%) in the placebo group (49 from progressive disease). At the time of the last analysis, median overall survival had n engl j med 357;2 november 22,
6 The new england journal of medicine Table 2. Response among Patients in the Intention-to-Treat Population and in Selected Subgroups.* Variable Lenalidomide (N = 76) Placebo (N = 75) P Value Response in the intention-to-treat population no. (%) Overall response 06 (60.2) 42 (24.0) <0.00 Complete response 28 (5.9) 6 (3.4) <0.00 Near-complete response 5 (8.5) 3 (.7) Partial response 63 (35.8) 33 (8.9) Stable disease 53 (30.) 97 (55.4) Progressive disease 3 (.7) 25 (4.3) Response could not be evaluated 4 (8.0) (6.3) Overall response in subgroups no./total no. (%) Previous exposure to Yes 26/53 (49.) /67 (6.4) No 80/23 (65.0) 3/08 (28.7) <0.00 β 2 -microglobulin mg per liter <2.5 36/5 (70.6) 8/48 (37.5) < /25 (56.0) 24/27 (8.9) <0.00 Previous no. of therapies 37/56 (66.) 7/57 (29.8) < /20 (57.5) 25/8 (2.2) <0.00 Previous stem-cell transplantation Yes 60/97 (6.9) 27/95 (28.4) <0.00 No 46/79 (58.2) 5/80 (8.8) <0.00 * P values were calculated with the use of a continuity-corrected Pearson chi-square test. There was no subgroup-by-treatment interaction for response rates with the use of the Breslow Day test for homogeneity. Percentages are for the rate of overall response among patients in selected subgroups of the intention-to-treat population. not been reached in the lenalidomide group and was 20.6 months in the placebo group (hazard ratio for death in the lenalidomide group, 0.66; 95% CI, 0.45 to 0.96; P = 0.03) (Fig. 2A). Overall survival was also significantly improved in the lenalidomide group among patients who had previously received (hazard ratio, 2.07; 95% CI,.02 to 4.2; P = 0.04) (Fig. 2B). Adverse Events The most frequently reported adverse events were neutropenia, muscle cramps, constipation, nausea, tremor, and dizziness. Table 3 lists all grade 3 or 4 adverse events. Patients in the lenalidomide group had a higher incidence of grade 3 neutropenia (25.0%) than did those in the placebo group (2.3%). However, grade 3 or 4 febrile neutropenia was rare (occurring in 3.4% of the patients in the lenalidomide group and in none of those in the placebo group). Grade 3 or 4 thrombocytopenia was twice as frequent in the lenalidomide group as in the placebo group (.4% vs. 5.7%). The incidence of grade 3 or 4 somnolence, constipation, or peripheral neuropathy (all toxic effects of ) was less than 0% in the two groups and rarely resulted in a dose reduction. Lenalidomide was associated with higher incidences of deep-vein thrombosis (4.0% vs. 3.5%) and pulmonary embolism (4.5% vs..2%) than was placebo. The rate of grade 3 or 4 thromboembolic complications was unrelated to the concomitant administration of erythropoietin. Such events occurred in 3 of 38 patients (7.9%) who received erythropoietin and 7 of 38 patients (2.3%) who did not receive erythropoietin in the lenalidomide group (P = 0.57) and in 3 of 36 patients (8.3%) who received erythropoietin and 5 of 39 patients (3.6%) who did not receive erythropoietin in the placebo group (P = 0.36). The proportion of patients who required more 228 n engl j med 357;2 november 22, 2007
7 Lenalidomide for Relapsed or Refractory Myeloma A Lenalidomide Placebo Patients (%) Months No. at Risk Lenalidomide Placebo B Patients (%) Lenalidomide with previous Lenalidomide without previous Placebo without previous Placebo with previous Months No. at Risk Lenalidomide without Lenalidomide with Placebo without Placebo with Figure 2. Kaplan Meier Curves for Overall Survival among All Patients and in Subgroups with and without Previous Exposure to Thalidomide. Panel A shows the estimates of median overall survival for the intention-to-treat population (not yet reached in the lenalidomide group and 20.6 months in the placebo group, P<0.00 by the log-rank test). Panel B shows the median overall survival among patients in the two study groups who received before study entry and those who did not receive (in the lenalidomide group, the median was not yet reached in either subgroup; in the placebo group, 23.5 months among those who did not receive and 8.2 months among those who did receive ; P = 0.04 by the log-rank test for the between-group comparison of patients who received and P = 0.2 for the between-group comparison of patients who did not receive ). than one dose reduction or interruption of lenalidomide or dexamethasone was similar in the two groups. The mean time until the first dose reduction or interruption of a study drug was also similar in the two groups (25 days in the lenalidomide group and 28 days in the placebo group). Dose reduction or interruption because of adverse events was more common in the lenalidomide group (occurring in 76.% of the patients) than in the placebo group (56.9%, P<0.00). There were deaths that were possibly related to a study drug: 5 in the lenalidomide group ( from cardiac arrest, from pulmonary embolism, from leukoencephalopathy, from pneumonia bacteria, and from sudden death) and 6 in the placebo group (3 from sepsis, from hepatic failure, from a cerebrovascular event, and from gastrointestinal hemorrhage). The primary reason for the discontinuation of treatment in the two groups was disease progression; 3 patients in the two groups (8.8%) discontinued treatment early because of adverse events. Granulocyte colony-stimulating factor was administered if only grade 3 or 4 myelosuppression occurred; with other grade 3 or 4 adverse events, the lenalidomide dose was reduced. In the n engl j med 357;2 november 22,
8 The new england journal of medicine Table 3. Grade 3 and 4 Adverse Events.* Event Lenalidomide (N = 76) Placebo (N = 75) Grade 3 Grade 4 Grade 3 Grade 4 number (percent) Hematologic disorder Neutropenia 44 (25.0) 8 (4.5) 4 (2.3) 0 Anemia 4 (8.0) (0.6) 2 (6.9) 0 Thrombocytopenia 7 (9.7) 3 (.7) 7 (4.0) 3 (.7) Febrile neutropenia 5 (2.8) (0.6) 0 0 Gastrointestinal disorder Constipation 3 (.7) 0 2 (.) 0 Diarrhea 5 (2.8) 0 4 (2.3) 0 Nausea 2 (.) General disorder Asthenia (6.2) 0 0 (5.7) 0 Fatigue (6.2) (0.6) 6 (3.4) 0 Pyrexia (0.6) 0 6 (3.4) 0 Peripheral edema 2 (.) 0 3 (.7) 0 Infection Upper respiratory infection 3 (.7) All other infection 5 (8.5) 2 (.) 9 (5.) 2 (.) Weight loss 3 (.7) 0 (0.6) 0 Musculoskeletal or connective-tissue disorder Muscle cramp (0.6) Back pain 4 (2.3) 0 3 (.7) 0 Bone pain 5 (2.8) 0 3 (.7) 0 Muscle weakness 3 (7.4) 0 8 (4.6) 0 Arthralgia (0.6) 0 3 (.7) 0 Neurologic disorder Headache (0.6) 0 (0.6) 0 Tremor 2 (.) 0 2 (.) 0 Dizziness (0.6) 0 (0.6) 0 Paresthesia (0.6) Insomnia 2 (.) 0 (0.6) 0 Respiratory, thoracic, or mediastinal disorder Cough 2 (.) 0 (0.6) 0 Nasopharyngitis (0.6) Dyspnea 4 (2.3) (0.6) 2 (.) (0.6) Vascular disorder Deep-vein thrombosis 6 (3.4) (0.6) 5 (2.9) (0.6) Pulmonary embolism 2 (.) 6 (3.4) (0.6) (0.6) Venous thromboembolism 3 (7.4) 7 (4.0) 6 (3.5) 2 (.) * Listed are data that were available on December 3, Percentages may not total 00 because of rounding. This condition was also described in the following terms: infections not otherwise specified, pneumonia, upper respiratory tract infection, upper respiratory viral infection, sepsis, bacterial infection, urinary tract infection, pharyngitis, nasopharyngitis, febrile neutropenia, oral candidiasis, oral fungal infection, primary atypical pneumonia, fungal sinusitis, herpes simplex, herpes zoster, herpes encephalitis, herpes viral infection, cytomegalovirus pneumonia, and viral infection. This condition was also described in the following terms: deep-vein thrombosis, pulmonary embolism, pulmonary infarction, thrombosis, phlebothrombosis, thrombophlebitis, superficial thrombophlebitis, venous thrombosis, thromboembolism, splenic-vein thrombosis, phlebitis, and superficial phlebitis. 230 n engl j med 357;2 november 22, 2007
9 Lenalidomide for Relapsed or Refractory Myeloma lenalidomide group, 38 patients (2.6%) received granulocyte colony-stimulating factor during the study. Of these patients, 23 (60.5%) received granulocyte colony-stimulating factor as the first step after having grade 3 or 4 neutropenia to maintain the 25-mg dose level. Among these 23 patients, 2 (52.2%) were able to continue with the 25-mg dose level of lenalidomide from the time of the first episode of grade 3 or 4 neutropenia until the last follow-up visit, as long as that period of time was at least 3 months. Discussion We found that in patients with relapsed or refractory multiple myeloma, lenalidomide plus dexamethasone increased the time to progression, the rate of response (both overall and complete responses), and overall survival, as compared with placebo plus dexamethasone. The median time to progression of.3 months and the 60.2% response rate in the lenalidomide group are among the highest values that have been reported in the treatment of relapsed or refractory multiple myeloma. These findings support the early use of lenalidomide in patients with progressive multiple myeloma. In addition, nearly one third of patients in our trial had previously received. Our data indicate that lenalidomide can be administered to patients who have received previous treatment with without deterioration of preexisting -related neuropathy; in our study, nearly 50% of such patients had a response to lenalidomide, with a median time to progression of 8.4 months. As compared with patients who had not been exposed to, patients who had previously been treated with the drug had received an additional year of treatment and had also received one more previous therapy. Given that current therapy includes and dexamethasone, this finding is encouraging for patients with disease that is resistant to treatment. The primary toxic effects of the lenalidomide regimen were hematologic, and we found them to be manageable with adjustment of the dose of lenalidomide. Neutropenia was managed with dose adjustments, the administration of granulocyte colony-stimulating factor, or both, whereas thromboembolic events were managed with anticoagulants. Lenalidomide was not associated with the peripheral neuropathy that is caused by long-term treatment with. In summary, we found that therapy with lena lidomide plus dexamethasone was more effective in patients with relapsed or refractory multiple myeloma than was therapy with placebo plus dexamethasone. Supported by Celgene. Drs. Dimopoulos, Harousseau, and San Miguel report receiving consulting and lecture fees from Celgene; Drs. Prince, Hellmann, and Facon, receiving consulting fees from Celgene; and Drs. Yu, Patin, Zeldis, and Knight, being employees of and holding equity in Celgene. No other potential conflict of interest relevant to this article was reported. We thank all the patients who participated in this trial, along with the nurses, the study contributors, and the investigators who recruited patients. Appendix In addition to the authors, the following investigators (listed according to city and country) participated in the study: Austria H. Ludwig (Vienna); Australia J. Catalano (Frankston), J. Szer (Melbourne), K. Taylor (Brisbane), P. Wood (Herston); Belgium M. Delforge (Leuven), A. Ferrant (Brussels); England J. Bird (Bristol), M. Streetly and K. Yong (London); France B. Coiffer (Pierre- Bénite), J.-P. Fermand (Paris); Germany R. Fenk (Dusseldorf), H. Goldschmidt (Heidelberg), H. Gollasch and U. Schneider (Berlin), M. Kropff (Muenster), A.D. Rascu (Erlangen); Israel D. Ben-Yehuda (Jerusalem), A. Nagler (Tel Hashomer), J.M. Rowe (Haifa); Italy M. Baccarani (Bologna), R. Fanin (Udine), M. Gobbi (Genoa), E. Morra (Milan); Northern Ireland M. Drake (Belfast); Poland L. Konopka (Warsaw); Spain A. Algere and J.-J. Lahuerta (Madrid), J. Baro (Valdecilla), J. Blade (Barcelona), F. Prosper (Pamplona); Switzerland F. Hitz (St. Gallen), C. Taverna (Zurich); Ukraine P. Kaplan (Dnepropetrovsk), E. Karamanesht (Kiev), T. Lysaya (Zhitomir), G. Pilipenko (Cherkassy). References. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, Ann Oncol 2005;6: Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2: Singhal S, Mehta J, Desikan R, et al. Antitumor activity of in refractory multiple myeloma. N Engl J Med 999;34: [Erratum, N Engl J Med 2000;342:364.] 4. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96: Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 200;2:99-5. n engl j med 357;2 november 22,
10 Lenalidomide for Relapsed or Refractory Myeloma 6. Garcia-Sanz R, González-Porras JR, Hernández JM, et al. The oral combination of, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;8: Kumar S, Anderson KC. Drug insight: as a treatment for multiple myeloma. Nat Clin Pract Oncol 2005;2: Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of administration in patients with neoplastic diseases. Am J Med 2004;7: Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002; 30: Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-503 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;00: Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;08: Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplan tation. Br J Haematol 998;02:5-23. Copyright 2007 Massachusetts Medical Society. 232 n engl j med 357;2 november 22, 2007
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America Donna M. Weber, M.D., Christine Chen, M.D., Ruben
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationREVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED APPROVAL BY FDA FOR TREATMENT OF MULTIPLE MYELOMA
Contact: Robert J. Hugin Brian P. Gill President and COO Senior Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationOriginal article. Introduction
Original article Annals of Oncology 15: 134 138, 2004 DOI: 10.1093/annonc/mdh026 Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil):
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus
More informationD.J. White MD MSc,* N. Paul PhD, D.A. Macdonald MD,* R.M. Meyer MD, and L.E. Shepherd MD ORIGINAL ARTICLE ABSTRACT KEY WORDS 1.
ORIGINAL ARTICLE Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial D.J. White MD MSc,*
More informationBortezomib, Thalidomide and Dexamethasone (VTD) 28 day
Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Indication First line treatment of multiple myeloma in patients who are eligible for stem cell transplantation. (NICE TA311) ICD-10 codes Codes with
More information(908) (908)
Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationMedian duration of transfusion independence was 8.2 months
December 8, 2014 Results from Phase III Study of REVLIMID (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS),
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Thrombocytopenia DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationThe drug cost of lenalidomide for people who remain on treatment for more than 26 cycles will be met by the company.
LENALIDOMIDE MDS NICE TA322 Treatment of patients with transfusion-dependent anaemia (< 8 consecutive weeks without RBC transfusions within 16 weeks prior to commencing treatment) due to low- or intermediate-1-risk
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationTitle A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Renal Impairment DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationPOMALIDOMIDE AND LOW DOSE DEXAMETHASONE
POMALIDOMIDE AND LOW DOSE DEXAMETHASONE INDICATION Multiple myeloma at third or subsequent relapse, i.e. after 3 previous treatments including both lenalidomide and bortezomib. (NICE TA427 -BLUETEQ required)
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationImpact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
(2011) 25, 1620 1626 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Impact of lenalidomide dose on progression-free survival in patients with relapsed
More informationSCIENTIFIC DISCUSSION. London, 15 November 2007 EMEA/37144/2008 EMEA/H/C/000089/II/0045
SCIENTIFIC DISCUSSION London, 15 November 2007 EMEA/37144/2008 EMEA/H/C/000089/II/0045 Invented name/name: Caelyx International non-proprietary name/common name: doxorubicin hydrochloride Extension of
More informationABSTRACTS 689, 901, 3668, and December 11, 2012
December 11, 2012 Data Evaluating Combination Treatments Including REVLIMID Plus Antibody Therapies in Patients with Various Difficult-to-Treat Forms of Non-Hodgkin Lymphoma Presented at the 54th American
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationSCIENTIFIC DISCUSSION
Product name: VELCADE Procedure No. EMEA/H/C/539/II/05 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel:(44-20) 74 18 84, fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in
SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationWALDENSTROM S macroglobulinemia (WM) is a
Treatment of Waldenstrom s Macroglobulinemia With Thalidomide By Meletios A. Dimopoulos, Athanassios Zomas, Nora A. Viniou, Vassiliki Grigoraki, Eleni Galani, Charis Matsouka, Olga Economou, Nikolaos Anagnostopoulos,
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationREVLIMID Dosing Guide
REVLIMID Dosing Guide Convenient Once-Daily Oral Dosing for MM, MCL, and MDS 1 REVLIMID (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationDRUG NAME: Pomalidomide
DRUG NAME: Pomalidomide SYNONYM(S): COMMON TRADE NAME(S): POMALYST CLASSIFICATION: miscellaneous Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.47 Subject: Revlimid Page: 1 of 6 Last Review Date: June 19, 2015 Revlimid Description Revlimid (lenalidomide)
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationPomalidomide and Dexamethasone INDICATIONS FOR USE:
Pomalidomide and INDICATIONS FOR USE: INDICATION Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationREVLIMID is only available through a restricted distribution program, REVLIMID REMS. Please see additional Important Safety Information on pages
REVLIMID is only available through a restricted distribution program, REVLIMID REMS. Please see additional Important Safety Information on pages 11-12 and accompanying full Prescribing Information, including
More informationREVLIMID [lenalidomide] capsules, for oral use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide]
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information* Dose may vary dependent on tolerability and co-morbidities
BC Cancer Protocol Summary for Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone Protocol Code Tumour Group Contact
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationCelgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer
November 22, 2013 Celgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationBCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLDREL Lymphoma, Leukemia/BMT Dr.
More informationDosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr Kyprolis carfilzomib for injection 10, 30, 60 mg per vial Antineoplastic Agent Amgen Canada Inc. 6775 Financial Drive, Suite 100 Mississauga,
More informationBCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone Protocol Code UMYPOMDEX Tumour Group Contact Physician Contact Pharmacist Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationDOSING & ADMINISTRATION FOR DARZALEX (daratumumab)
JUNE 2017 UPDATE DOSING & ADMINISTRATION FOR DARZALEX (daratumumab) Indications and mechanisms of action 1 How DARZALEX is supplied DARZALEX (daratumumab) is indicated: in combination with lenalidomide
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationPomalidomide and Dexamethasone Therapy
INDICATIONS FOR USE: Pomalidomide and Therapy Regimen Code INDICATION ICD10 Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationOnline Supplementary Data. Country Number of centers Number of patients randomized
A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMultiple myeloma (MM) is a B-cell malignancy characterized
This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies,
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationNew Drugs for Myeloma. Key Words. Bortezomib Lenalidomide Multiple myeloma Thalidomide
The Oncologist Myelomas New Drugs for Myeloma PAUL G. RICHARDSON, CONSTANTINE MITSIADES, ROBERT SCHLOSSMAN, NIKHIL MUNSHI, KENNETH ANDERSON Dana-Farber Cancer Institute, Harvard Medical School, Boston,
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationFDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
October 12, 2012 FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of
More informationOptimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
REVIEW (2011) 25, 749 760 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus
More information